By unraveling the molecular mechanisms associated with its effects on inflammation, adhesion, migration, and the TLR4/NF‐κB/CCR2 signaling pathway, valuable insights were provided into potential therapeutic targets for the management of AAA. The gene discussed is CCR2; the disease is triple-A syndrome.